Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Trading 04-20 13:30:10 EDT

1.20

+0.48

+66.76%

High1.52	Low1.05	Vol203.67M
Open1.33	D1 Closing0.7196	Amplitude65.31%
Mkt Cap2.51M	Tradable Cap2.43M	Total Shares2.09M
T/O260.72M	T/O Rate10,073.20%	Tradable Shares2.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":1.2,"timestamp":1776706209557,"preClose":0.7196,"halted":0,"volume":203669925,"delay":0,"changeRate":0.6675931072818231,"floatShares":2021898,"shares":2088806,"eps":-17.044554,"marketStatus":"Trading","change":0.4804,"latestTime":"04-20 13:30:10 EDT","open":1.33,"high":1.52,"low":1.05,"amount":260717891.3594925,"amplitude":0.653141,"askPrice":1.2,"askSize":15050,"bidPrice":1.19,"bidSize":1875,"shortable":0,"etf":0,"ttmEps":-17.044554,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776715200000},"marketStatusCode":2,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":0.7196,"preHourTrading":{"tag":"盘前","latestPrice":1.3298,"preClose":0.7196,"latestTime":"09:29 EDT","volume":45462006,"amount":54697680.711908996,"timestamp":1776691799998,"change":0.6102,"changeRate":0.847971,"amplitude":1.014452},"postHourTrading":{"tag":"盘后","latestPrice":0.6842,"preClose":0.7196,"latestTime":"19:59 EDT","volume":84890,"amount":59263.789053,"timestamp":1776470372550,"change":-0.0354,"changeRate":-0.049194,"amplitude":0.070178},"volumeRatio":44.192813},"requestUrl":"/m/hq/s/CMND/wiki","defaultTab":"wiki","newsList":[{"id":"2628265087","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2628265087","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628265087?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:34","pubTimestamp":1776692072,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nAQN2LVC04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628422427","title":"Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628422427","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628422427?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:15","pubTimestamp":1776683722,"startTime":"0","endTime":"0","summary":"Clearmind Medicine reported positive top-line safety results from its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on April 20, 2026.Data from third cohort showed drug candidate was well tolerated at highest dose tested so far, with no serious adverse events reported.Study met its primary endpoint on safety and tolerability, supporting continued development of CMND-100 as a potential non-hallucinogenic oral treatment option for Alcohol Use Disorder.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL6T4625:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4585","SG9999014021.USD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014013.SGD","BK4007","SG9999014039.USD","BK4112","CMND","NDAQ","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628219742","title":"Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2628219742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628219742?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:15","pubTimestamp":1776683703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130GP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628427957","title":"Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628427957","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628427957?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:15","pubTimestamp":1776683700,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April  20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and development ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276876/0/en/Clearmind-Medicine-Announced-Positive-Top-Line-Safety-Results-CMND-100-Proprietary-Psychedelic-Treatment-Meets-Primary-Endpoint-in-AUD-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627212996","title":"Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627212996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627212996?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:27","pubTimestamp":1776353261,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a primary endpoint achievement, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearminds-cmnd-100-meets-primary-endpoint-in-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearminds-cmnd-100-meets-primary-endpoint-in-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627721292","title":"Clearmind announces DSMB recommendation to continue CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627721292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627721292?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:26","pubTimestamp":1776353212,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced Wednesday that its independent Data and Safety Monitoring Board has completed its review and issued a positive ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-announces-dsmb-recommendation-to-continue-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-announces-dsmb-recommendation-to-continue-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627879032","title":"Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2627879032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627879032?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:16","pubTimestamp":1776259005,"startTime":"0","endTime":"0","summary":"Clearmind received a positive recommendation from an independent Data and Safety Monitoring Board to continue its FDA-approved Phase I/IIa trial of CMND-100 in patients with moderate to severe Alcohol Use Disorder.Top-line safety results have already been presented internally to the board, showing CMND-100 was well tolerated with no serious adverse events reported.Clearmind will advance to fourth cohort, raising tested dose to 160 mg.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely respons","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL7fBpnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627579289","title":"Clearmind Medicine Inc - Cmnd-100 Well Tolerated With No Serious Adverse Events in Third Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2627579289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627579289?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:30","pubTimestamp":1776252600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA9DPH8H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627289547","title":"Clearmind Medicine Inc - to Proceed to Fourth Cohort, Increase Cmnd-100 Dose to 160Mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2627289547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627289547?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:30","pubTimestamp":1776252600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA9DPH8H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627289391","title":"Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing Cmnd-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627289391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627289391?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:30","pubTimestamp":1776252600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA9DPH8H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627899612","title":"Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627899612","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627899612?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:30","pubTimestamp":1776252600,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April  15, 2026 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and development","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274332/0/en/Clearmind-Medicine-Announces-Positive-Data-Safety-Monitoring-Board-Recommendation-in-ongoing-CMND-100-clinical-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627421337","title":"Clearmind Medicine issues $1.75 million convertible notes, raises $1.58 million cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421337","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421337?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:02","pubTimestamp":1776196941,"startTime":"0","endTime":"0","summary":"Clearmind Medicine delivered notice on April 14, 2026 to issue US$ 1.75 million of convertible promissory notes to CLA investors.Purchase price was set at 90% of principal, implying cash proceeds of US$ 1.575 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3P0QY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441678","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441678?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:15","pubTimestamp":1776172541,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, TravereWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nL6N40X0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","CRDO","NNOX","ORCL","TSLQ","CAT","CWVX","LCID","TE","AU","GM","CRWV","FRDU","NEM","TSLT","CMND","BE","TSLG","KMX","GSAT","DOW","DAL","SPOG","TSLA","AVNS","GRCE","BLK","CMPS","TSLW","ORCU","TVTX","HL","AAL","EAF","TESL","UAL","BEZ","NWMX","AVXL","CRWG","TSLL","JNJ","SPOT","WMG","TLA","ACI","F","HOTH","LUV","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627484443","title":"BUZZ-Clearmind Medicine rises after alcohol addiction drug shows safety in early trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627484443","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627484443?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:44","pubTimestamp":1776167077,"startTime":"0","endTime":"0","summary":"BUZZ-Clearmind Medicine rises after alcohol addiction drug shows safety in early trial** Shares of biotech firm Clearmind Medicine CMND.O shares rise 30.83% to $1.87 premarket** Co says its experimental oral drug CMND-100 is being tested for alcohol use disorder, a condition where people struggle to control heavy drinking** Says the drug met the main goal of safety in an early-stage clinical trial, with no serious side effects reported** Adds the treatment was well tolerated, including at the highest dose tested so far** Says the international study is testing the drug in people with moderate to severe alcohol use disorder and supports further development** As of last close, stock down ~21% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nL4N40X15J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443358","title":"Clearmind Medicine Inc - Third Cohort Results Show High Safety Profile for Cmnd-100 With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627443358?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:32","pubTimestamp":1776166320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA802YNW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443330","title":"Clearmind Medicine Inc - Phase I/Iia Trial Evaluates Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Cmnd-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627443330?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:32","pubTimestamp":1776166320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA802YNW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443296","title":"Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443296","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627443296?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:32","pubTimestamp":1776166320,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April  14, 2026 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and development","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/14/3273236/0/en/Clearmind-Medicine-s-CMND-100-Meets-Primary-Endpoint-in-FDA-Approved-Phase-I-IIa-Clinical-Trial-for-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LABU","BK4588","BK4585","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502136","title":"Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502136?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:55","pubTimestamp":1775138153,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on treatment completion, a publicati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-treatment-follow-up-for-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-treatment-follow-up-for-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310630","title":"Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310630","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310630?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:32","pubTimestamp":1774873920,"startTime":"0","endTime":"0","summary":"Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March  30, 2026 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264626/0/en/Clearmind-Medicine-Announces-Successful-Completion-of-Treatment-and-Follow-up-for-18-Participants-in-its-Ongoing-Phase-I-IIa-Clinical-Trial-of-CMND-100-for-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622825094","title":"BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2622825094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622825094?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:45","pubTimestamp":1774611912,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health DisordersClearmind Medicine Inc CMND.O:CLEARMIND MEDICINE FILES PATENT APPLICATION ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F02M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.4378},{"period":"1month","weight":0.0637},{"period":"3month","weight":-0.7122},{"period":"6month","weight":-0.9812},{"period":"1year","weight":-0.9839},{"period":"ytd","weight":-0.6024}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.20421},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.01702},{"month":6,"riseRate":0.333333,"avgChangeRate":0.080414},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}